Disease relevance of K-1900

• Accordingly, we have combined nimorazole, the only hypoxic radiosensitizer shown to significantly improve local control in head and neck cancer, with continuous hyperfractionated accelerated radiation therapy (CHART) [1].
• METHODS AND MATERIALS: Twenty-two patients with locally advanced (stage IV) squamous cell carcinoma of the head and neck were treated with escalating doses of nimorazole given concomitantly with CHART (three fractions of 1.5 Gy per day, spaced 5 1/2 hours apart, on 12 consecutive days) [1].
• Nimorazole toxicity was somewhat greater than with once daily administration in previous studies [2].
• 417 patients suffering from intestinal amoebiasis were randomly allocated to 6 different treatment groups in a controlled study in 3 District Hospitals in Kenya. The patients received either aminosidine (A), etophamide (E), nimorazole (N), or the combinations NA, NE, EA [3].
• Cure rates for bacterial vaginosis by nimorazole were 70.0% (21/30), 83.3% (25/30), and 90.0% (27/30) in Group I, II, and III, respectively [4].

High impact information on K-1900

• This, in light of the fact that other well-tolerable hypoxic cell sensitizers such as nimorazole with clinically proven efficacy at daily oral doses of < 3 g are available, limits the potential usefulness of ISO for radiation oncology [5].
• Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer [1].
• CONCLUSIONS: Comparison with a historical group of patients, treated with the CHART regimen alone and matched for irradiation volume and technique, showed that nimorazole did not increase the severity of acute normal tissue radiation effects [1].
• In the present study the comparative in-vitro and in-vivo efficacy of Go 10213 was compared with those of metronidazole, secnidazole, tinidazole, ornidazole and nimorazole against a metronidazole-resistant strain of T. vaginalis [6].
• A tendency to a dose-dependent variation in the apparent volume of distribution, total body clearance and elimination half life suggest non-linear pharmacokinetics of nimorazole [7].

Chemical compound and disease context of K-1900

• Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole [8].

Biological context of K-1900

• The pharmacokinetics of the hypoxic radio-sensitizer nimorazole were studied in 19 individuals after single oral doses of between 0.5-3.5 g [7].

Anatomical context of K-1900

• CONCLUSION: Nimorazole significantly improves the effect of radiotherapeutic management of supraglottic and pharynx tumors and can be given without major side-effects [9].

Associations of K-1900 with other chemical compounds

• Thirty-three asymptomatic children were studied before and after treatment with metronidazole (Nimorazol) [10].
• Analysis of the basic 5-nitroimidazole nimorazole in blood by reversed-phase high-performance liquid chromatography, and its application to pharmacokinetic studies in individual mice [11].
• 4. However, with the weaker bases, Ro 03-8800 and nimorazole (morpholino derivatives with pKa = 6.3 and 5.2 respectively) the e.r. remained constant over a wide pHe range [12].

Analytical, diagnostic and therapeutic context of K-1900

• Encouraging tumor responses have been seen in the patients receiving nimorazole with every radiotherapy fraction [1].
• It was suggested that sanazole may be more suitable for clinical trials than nimorazole [13].

References